Opterion Health

Executive Summary

Opterion Health AG, a Swiss digital health and AI company founded in 2016, is pioneering a novel non-glucose-based osmotic agent for peritoneal dialysis (PD). Current glucose-based PD solutions are associated with metabolic complications and peritoneal membrane damage, limiting the effective treatment window. Opterion's technology aims to address these shortcomings, potentially improving patient outcomes and extending the duration patients can remain on PD. The company has reached Phase 1 clinical development, indicating initial safety testing in humans. Given the large and growing global dialysis patient population—over 3 million patients worldwide, with PD adoption increasing due to home-based therapy advantages—Opterion's innovation could capture significant market share if proven safe and efficacious.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Clinical Trial Results40% success
• H1 2027Strategic Partnership with Dialysis Provider30% success
• Q2 2026Regulatory Meeting or IND Update60% success